Search

Your search keyword '"mixed cryoglobulinaemia vasculitis"' showing total 6 results
Start Over Descriptor "mixed cryoglobulinaemia vasculitis"
6 results on '"mixed cryoglobulinaemia vasculitis"'

1. Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals.

Author

Barbieri, Diego, García-Prieto, Ana, Torres, Esther, Verde, Eduardo, Goicoechea, Marian, and Luño, José

Subjects
*VASCULITIS, *HEPATITIS, *EPSTEIN-Barr virus diseases, *THERAPEUTICS, *HEPATITIS C virus
Abstract

Highlights from the article: Mixed cryoglobulinaemia (MCG) is one of the most severe extrahepatic hepatitis C virus (HCV)-associated complications, MCG prognosis relies on HCV response to antiviral treatment We report a case of a patient with chronic HCV infection treated with DAA who developed MCG vasculitis despite the For HCV (including hepatitis C virus (HCV)-polymerase chain reac-.

Published
2019
Full Text
View/download PDF

2. Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis

Author

Patrice Cacoub, Mark Bondin, Anna Linda Zignego, Jean-Michel Pawlotsky, Gestionnaire, Hal Sorbonne Université, Università degli Studi di Firenze = University of Florence (UniFI), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de bactériologie, virologie, hygiène [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] (I3), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Vasculitis, medicine.medical_specialty, Population, Hepacivirus, Antiviral Agents, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Adrenal Cortex Hormones, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Severity of illness, medicine, Humans, Pharmacology (medical), Precision Medicine, education, Expert Testimony, Survival rate, Survival analysis, Pharmacology, education.field_of_study, Mixed cryoglobulinaemia vasculitis, business.industry, Mortality rate, Disease Management, Plasmapheresis, Hepatitis C, Hepatitis C, Chronic, medicine.disease, Survival Analysis, 3. Good health, Infectious Diseases, Cryoglobulinemia, 030220 oncology & carcinogenesis, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 030211 gastroenterology & hepatology, Rituximab, business, Systemic vasculitis
Abstract

International audience; Mixed cryoglobulinaemia vasculitis (CryoVas) is a small-vessel systemic vasculitis caused by deposition of mixed cryoglobulins and is characterized by a wide range of clinical symptoms. HCV is the primary cause of CryoVas, which is associated with significant morbidity and mortality. The mortality rate among patients with HCV-associated CryoVas is 3× that of the general population, with a 63% 10-year survival rate. First-line treatment for CryoVas is anti-HCV therapy because viral clearance is associated with clinical improvement. The introduction of highly effective, interferon-free, direct-acting antiviral regimens provides additional treatment options for these patients. Here, we review recent studies investigating the effect of antiviral therapy on HCV-associated CryoVas and provide expert opinion for health-care professionals managing these patients.

Published
2018

3. Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals

Author

Diego Barbieri, José Luño, Ana García-Prieto, Marian Goicoechea, Eduardo Verde, and Esther Torres

Subjects
hepatitis C virus, medicine.medical_specialty, membranoproliferative glomerulonephritis, Hepatitis C virus, 030232 urology & nephrology, Glomerular Disease, medicine.disease_cause, DIRECT ACTING ANTIVIRALS, Gastroenterology, mixed cryoglobulinaemia vasculitis, Virological response, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Membranoproliferative glomerulonephritis, medicine, Antiviral treatment, direct-acting antivirals, Mixed cryoglobulinaemia, Transplantation, business.industry, virus diseases, Hepatitis C, medicine.disease, digestive system diseases, Nephrology, sustained virological response, business, Vasculitis
Abstract

Mixed cryoglobulinaemia (MCG) is one of the most severe extrahepatic hepatitis C virus (HCV)-associated complications, and could involve several organs, including the kidney. MCG prognosis relies on HCV response to antiviral treatment and has changed over the last years, especially after the introduction of new direct acting antivirals (DAA). MCG persistence despite sustained virological response (SVR) is uncommon and has a poorly known meaning and prognosis. We report a case of a patient with chronic HCV infection treated with DAA who developed MCG vasculitis despite the SVR.

Published
2018

5. Hepatitis C virus and autoimmunity

Author

Barbara C. Böckle and N Sepp

Subjects
Lymphoma, business.industry, Mixed cryoglobulinaemia vasculitis, Hepatitis C virus, Immunology, Autoantibody, Hepatitis C, Review Article, medicine.disease_cause, medicine.disease, Virology, Autoimmunity, Rheumatology, medicine, Extrahepatic manifestations, business, Autoimmune mechanism, Autoantibody production
Abstract

Hepatitis C virus infection is associated with several extrahepatic manifestations. About 60% of patients infected with HCV develop at least one extrahepatic manifestation. The majority of these diseases seem to be triggered through autoimmune mechanisms, such as autoantibody production, autoreactive T cells and complex autoimmune mechanisms leading to systemic autoimmune disorders. In this review we categorize these diseases into three groups according to the main pathogenetic process involved, in particular B-cell-mediated, T-cell-mediated and complex autoimmune systemic diseases.

Published
2010

6. Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals.

Author

Barbieri D, García-Prieto A, Torres E, Verde E, Goicoechea M, and Luño J

Abstract

Mixed cryoglobulinaemia (MCG) is one of the most severe extrahepatic hepatitis C virus (HCV)-associated complications, and could involve several organs, including the kidney. MCG prognosis relies on HCV response to antiviral treatment and has changed over the last years, especially after the introduction of new direct acting antivirals (DAA). MCG persistence despite sustained virological response (SVR) is uncommon and has a poorly known meaning and prognosis. We report a case of a patient with chronic HCV infection treated with DAA who developed MCG vasculitis despite the SVR.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results